Video
Dr. Bukavina and Dr. Psutka share take-homes from kidney cancer epidemiology paper
Author(s):
“We need to continue to push the field forward, and the way we do that is to evaluate the risk factors and to stratify patients based on their risk factors and their genetic components,” says Laura Bukavina, MD, MPH.
Video Player is loading.
In this video, Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discuss the take-home messages from the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Psutka is an associate professor of urology at University of Washington Medical Center, Seattle.
Related Videos
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
Investigators evaluate tamsulosin use in pediatric patients
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Related Content
